Real‐world data on EFG in gMG are still very limited [31] Our experience has the weaknesses of being an open, uncontrolled study, on a small number of patients, but comes from real practice and included not only anti‐AchR and MuSK, but also LRP4 and triple‐negative MG patients, subgroups that were not considered by clinical trials but deserve more attention in future studies. The gene discussed is MUSK; the disease is myasthenia gravis.